Bio-India Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 6.70 M
- Company Age 24 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.15 Cr
- Revenue Growth 4.57%
- Profit Growth -73.35%
- Ebitda 239.60%
- Net Worth -1.85%
- Total Assets 15.50%
About Bio-India Pharma
Bio-India Pharma Private Limited (BPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 June 2000 and has a history of 24 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 6.70 M.
The company currently has active open charges totaling ₹4.15 Cr.
Savio Dcosta and Prabhakar Vithal serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U15100MH2000PTC127200
-
Company No.
127200
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Jun 2000
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Bio-India Pharma Private Limited offer?
Bio-India Pharma Private Limited offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs, Health Conditions, Pain Relief, Homeopathy Medicines, Dilutions, Bio Combinations, Fever.
Who are the key members and board of directors at Bio-India Pharma?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Savio Dcosta | Whole-Time Director | 14-Jun-2000 | Current |
Prabhakar Vithal | Director | 14-Jun-2000 | Current |
Financial Performance of Bio-India Pharma.
Bio-India Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.57% increase. The company also saw a substantial fall in profitability, with a 73.35% decrease in profit. The company's net worth dipped by a decrease of 1.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-India Pharma?
In 2023, Bio-India Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹4.15 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 2.43 Cr
- Syndicate Bank : 1.22 Cr
- Sidbi : 0.50 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
04 Jun 2021 | Canara Bank | ₹9.33 M | Open |
14 Oct 2020 | Sidbi | ₹5.00 M | Open |
23 Jun 2020 | Canara Bank | ₹0.13 M | Open |
17 Jun 2020 | Canara Bank | ₹1.88 M | Open |
17 Nov 2017 | Canara Bank | ₹1.30 Cr | Open |
How Many Employees Work at Bio-India Pharma?
Bio-India Pharma has a workforce of 64 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-India Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-India Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.